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ABSTRACT
Background and Objectives: Patent ductus arteriosus (PDA) is associated with increased morbidity and mortality in pre-
mature infants. Therefore, an early diagnosis and treatment of a hemodynamically significant PDA are very important. A wid-
ened pulse pressure is considered to be a well known clinical sign of a PDA in older infants and children; however, whether 
this is also applicable in the case of preterm infants remains to be confirmed. The aims of this study were to investigate the 
change in blood pressure (BP) before and after medical treatment of a PDA with indomethacin and to evaluate if the change 
in the pulse pressure in preterm infants with a medically treated PDA could be used as a reliable clinical predictor of a hemo-
dynamically significant PDA. Subjects and Methods: Between January 2005 and June 2009, a retrospective analysis was 
performed in preterm infants with a hemodynamically significant PDA (PDA group, n=72) and preterm infants without a 
PDA (control group, n=72) at the Chonnam National University Hospital Neonatal Intensive Care Unit. The PDA was closed 
by treatment with indomethacin. The BP was compared between the two groups over the seven days after the first dose of 
indomethacin. Results: In preterm infants with a hemodynamically significant PDA, the mean systolic (55.1±6.0 mmHg) 
and diastolic BPs (31.4±6.2 mmHg) were lower than those in the controls (mean systolic BP 58.0±6.4 mmHg, mean diastolic 
BP 34.7±6.0 mmHg) before indomethacin treatment. When the ductus arteriosus was successfully closed by indomethacin 
treatment, there was a gradual increase in both the systolic and diastolic BPs without any change in the pulse pressure. Con-
clusion: The results of this study show that a widened pulse pressure is not a useful clinical sign of a hemodynamically sig-
nificant PDA in preterm infants. However, low systolic and diastolic BPs may be useful clinical signs of a hemodynamically 
significant PDA in preterm infants. If the systolic and diastolic BP is low, a PDA should be considered and echocardiography 
should be performed for early diagnosis and treatment. (Korean Circ J 2011;41:203-208)
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Introduction
The ductus arteriosus normally undergoes spontaneous 
closure within 24 to 48 hours after birth, in full-term infants. 
However, in 20% to 60% of the cases of premature infants, the 
ductus commonly remains open for many days after birth.
1)2) 
Significant left-to-right shunting across a patent ductus arte-
riosus (PDA) in premature infants is associated with heart fa-
ilure, intraventricular hemorrhage, necrotizing enterocolitis, 
and kidney injury as well as chronic lung disease, which leads 
to an increased morbidity and mortality.
3-7) Therefore, diagno-
sis and treatment of a hemodynamically significant PDA in a 
timely manner is very important. 
A PDA causes a decrease in the diastolic pressure resulting 
in a widened pulse pressure.
8-10) Although this has been con-
firmed in older infants and children, it has not been confirm-
ed in small preterm infants, who are often critically ill and have 
left-to-right shunting as a result of the PDA.
4)11)
The effect of PDA closure on the pulse pressure and blood 
pressure (BP) in preterm infants has not been well document-
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widened pulse pressures due to disproportionate reduction 
in the diastolic BP as compared to the systolic BP.
12)13) Howev-
er, others have reported that a hemodynamically significant 
PDA in very preterm infants is associated with reduction in 
both the systolic and diastolic BPs and that the pulse pressure 
is not significantly affected.
9)11)14)
The goals of this retrospective study were to investigate the 
change in BP before and after medical treatment of a PDA 
with indomethacin; and to determine if the change in the pulse 
pressure could be used as a reliable clinical predictor of a he-
modynamically significant PDA in preterm infants. 
Subjects and Methods
Patient population 
The records of all neonates less than 37 weeks gestational 
age (GA) and with a PDA treated with indomethacin were re-
viewed. There were a total of 3,546 neonates admitted to the 
Neonatal Intensive Care Units of the Chonnam National Uni-
versity Hospital from January 2005 to July 2009. There were 
1,812 preterm infants and 343 of them had a PDA. Seventy-
two infants, who had a hemodynamically significant PDA 
within 72 hours after birth, had undergone treatment with in-
domethacin and the ductus arteriosus subsequently closed af-
ter the treatment, were included in the study. The closure of 
PDA was confirmed by echocardiography and if the PDA re-
mained open, these  patients were excluded from this study. 
Each infant with a PDA was matched with an infant without 
a PDA. The matching criteria were: a similar GA (±1 week), 
birth weight (±100 g), ventilatory support, and severity of the 
respiratory distress syndrome. The following clinical data 
were recorded: GA, birth weight, gender, the day of diagnosis 
of the PDA, and the day on which indomethacin therapy was 
started. Neonates with severe combined diseases that could 
influence the BP were excluded from this study. The severe 
diseases such as major congenital malformations, congenital 
anomalies of the heart; except for a patent foramen ovale, 
renal or gastrointestinal abnormalities, persistent pulmonary 
hypertension, urinary output less than 1 mL/body weight per 
hour during the preceding 12 hours, recent bleeding within 
the last 48 hours, a periventricular or intraventricular hemor-
rhage more than grade 3, a platelet count less than 50,000/mm
3, 
sepsis, and a surgical closure of the PDA, were excluded from 
this study. 
 
Methods 
Blood pressure measurement
BP was measured either directly using an indwelling um-
bilical arterial catheter (UAC) or a radial arterial type of moni-
toring with General Electric DASH 3000 monitor (General 
Electric Systems, Milwaukee, USA), General Electric DASH 
4000 monitor (General Electric Systems, Milwaukee, USA), 
Intellivue MP70 (Philips Medical Systems, Suresnes, France) 
or indirectly using the oscillometric monitoring with General 
Electric DASH 3000 monitor (General Electric Systems, Mil-
waukee, USA), General Electric DASH 4000 monitor (Gen-
eral Electric Systems, Milwaukee, USA), Agilent M1205A mo-
nitor (Agilent technologies Co., Boeglingen, Germany), Cri-
tikon Neonatal Cuff (General Electric Systems, Juarez, Mexi-
co).
15) If direct measurement was available, the BP was re-
corded using it and if not, oscillometric measurement was 
exclusively used. If the UAC or radial artery catheter had been 
removed before the infant was 1 week old, oscillometric meas-
urements were used. The pulse pressure was computed as the 
systolic BP minus the diastolic BP. From the recorded BP taken 
at every 3 hours, the daily mean systolic, diastolic, and pulse 
pressure measurements for each infant were calculated from 
24 hours before the first dose of indomethacin upto seven days 
after the first dose of indomethacin. The BP in the control 
group was recorded in the same manner. If one of the patients 
in the PDA group received indomethacin on the fourth day 
after birth, the BP of a control with a similar GA (±1 week) 
and BW (±100 g), from the day before the initiation of indo-
methacin upto seven days after indomethacin treatment, from 
the the third day to the eighth day, were included in the analy-
sis. BP support was provided whenever the mean arterial pres-
sure (in torrs) was lower than the GA (in weeks), as suggest-
ed by Lee et al.
16) The protocol in our institution is to give fluid 
boluses (NaCl 0.9%) of 10 mL/kg intravenously in cases with 
hypotension, followed by inotropes if the fluid boluses failed 
to correct the hypotension. For the purpose of this study, in-
fants which received fluid boluses or inotropes during the first 
48 hours of life, were not excluded from the study.
Diagnosis of patent ductus arteriosus 
The diagnosis of PDA and the decision to treat were made on 
the basis of clinical criteria with echocardiographic (Acuson 
128XP/10 color flow ultrasound system, Simens Medical So-
lutions, Malvern, Pennsylvania, USA; Agilent SONOS 5500, 
Philips Medical Systems, Andover, Massachusetts, USA; iE33 
ultrasound system, Philips Medical Systems, Andover, Mas-
sachusetts, USA) confirmatory findings. The definition of a 
hemodynamically significant PDA was based on the previ-
ously established criteria and was defined by the presence of 
at least two of the following three parameters: a left atrium/
aorta ratio of more than 1.4 : 1, a left ventricle/aorta ratio of 
more than 2.1 : 1, and the narrowest ductal diameter of more 
than 1.5 mm.
17)
Treatment of patent ductus arteriosus
Each infant received three doses of i.v. indomethacin (Ly-
ometacen; Chiesi Farmaceutici, Parma, Italy), 0.2 mg/kg at 
12 hours intervals followed by two doses of 0.1 mg/kg each Ui Joung Han, et al.   205
after 24 and 48 hours. Surgical ligation of the ductus was per-
formed, when the ductus did not close after two or three co-
urses of indomethacin treatment or when a pharmacological 
treatment was contraindicated (n=16). Before administering 
the next dose of indomethacin, echocardiography was per-
formed and if the PDA had closed, no additional indometh-
acin was given.
Data analysis 
The results were analyzed in two different subgroups ac-
cording to the birth weight: less than 1,500 g (n=67) and more 
than 1,500 g (n=77) and in two different subgroups accord-
ing to the GA: less than 30 weeks (n=58) and more than 30 
weeks (n=86). In each of the two subgroups, the mean GA and 
BW did not differ significantly between the PDA group and 
the control group (Table 1 and 2).
Results were expressed as the mean±standard deviation 
and statistically significant differences were set at p<0.05. 
Statistical Package for the Social Sciences for Windows (ver-
sion 18.0) was used for analyzing the data. The differences in 
systolic BP, diastolic BP and pulse pressure were evaluated by 
an independent samples t-test and paired t-test.
Results
Retrospective data were collected on the premature in-
fants which met the inclusion criteria. Seventy-two preterm 
infants with a hemodynamically significant PDA and the same 
number of controls were analyzed. The mean GA, birth wei-
ght, mode of delivery, and sex were comparable between the 
PDA group and the control group (Table 3). 
The mean systolic (55.1±6.0 mmHg) and diastolic BPs 
(31.4±6.2 mmHg) were significantly lower in the PDA group 
than in the control group (systolic BP of 58.0±6.0 mmHg, dia-
stolic BP of 34.7±6.0 mmHg) before indomethacin treatment 
(p=0.006, p=0.002 respectively) (Fig. 1).
The mean systolic and diastolic BPs increased significantly 
and steadily in the PDA group during the seven days after in-
domethacin treatment was started. In the control group, the 
mean systolic BP increased steadily and the diastolic BP in-
creased by the third day of BP measurement. There were sig-
nificant differences in the systolic and diastolic BPs between 
the two groups. The systolic BPs between the PDA group and 
the control group respectively were as follows: On the first 
day 54.0±5.1 vs. 59.8±6.2 mmHg (p<0.001); on the second 
day: 57.5±5.6 vs. 62.2±5.8 mmHg (p=0.005), on the third 
day: 58.8±5.5 vs. 61.0±4.6 mmHg (p=0.014). The diastolic 
BPs between the PDA group and the control group respec-
tively were as follows: on the first day: 30.9±4.7 vs. 36.3±4.7 
mmHg (p<0.001); on the second day: 33.8±6.0 vs. 38.3±5.2 
mmHg (p=0.001); on the third day: 35.6±5.9 vs. 37.7±5.7 
mmHg (p=0.009). The infants with a PDA had lower mean 
systolic and diastolic BPs than the controls from the day be-
fore indomethacin treatment was started upto the third day 
after indomethacin treatment. The pulse pressures increased 
slightly after four days of indomethacin treatment in the two 
study groups, but were not significantly different at any given 
time between the PDA group and the control group (Fig. 1).
Infants with a birth weight more than 1,500 g   
During the study period, the average mean systolic and dia-
stolic BPs increased in the infants with a birth weight more 
than 1,500 g. The diastolic BPs were lower in the PDA group 
than in the control group but the differences were small and 
were not statistically significant. There were no significant dif-
ferences in the pulse pressures between the two groups (Fig. 2). 
Table 1. Mean GA and mean BW in the PDA group and the control 
group according to the infants BM
PDA group Control group p
Infants <1,500 g  (n=39) (n=28)
Mean GA (weeks) 28.2±2.0 28.1±1.3 NS
Mean BW (g) 1133±219 1193±213 NS
Infants ≥1,500 g (n=33) (n=44)
Mean GA (weeks) 32.9±1.7 32.6±1.9 NS
Mean BW (g) 2158±522 2037±419 NS
Data expressed as mean±standard deviation. GA: gestational age, 
PDA: patent ductus arteriosus, BW: birth weight, NS: not signifi-
cant
Table 2. Mean GA and mean BW in the PDA group and the control 
group according to the infants GA
PDA group Control group p
Infants <30 weeks  (n=32) (n=26)
Mean GA (weeks) 27.4±1.2 27.9±1.0 NS
Mean BW (g) 1133±266 1186±223 NS
Infants ≥30 weeks (n=40) (n=46)
Mean GA (weeks) 32.7±1.7 32.7±1.9 NS
Mean BW (g) 1978±609 2004±437 NS
Data expressed as mean±standard deviation. GA: gestational age, 
PDA: patent ductus arteriosus, BW: birth weight, NS: not significant
Table 3. Clinical characteristics of the preterm infants in the PDA 
and the control groups 
Variable
PDA group
(n=72)
Control group
(n=72)
p
Cesarean/Vaginal  54/18 51/21 NS
Birth weight (g)  1603±643 1709±544 NS
Male/Female  37/35 39/33 NS
Ventilatory support  63 63 NS
Gestational age (weeks) 30.4±3.0 30.9±2.8 NS
≤28  23 17
29-32  24 30
33-36  25 25
PDA: patent ductus arteriosus, NS: not significant206   BP and Pulse Pressure in Preterms After Treatment of PDA
than in the control group; however, the difference was not 
statistically significant. In addition, there were no significant 
differences in the pulse pressures between the two groups 
(Fig. 4).
Infants with a gestational age less than 30 weeks 
The mean systolic and diastolic BPs in the PDA group in-
creased daily from the day before indomethacin treatment up-
The systolic and diastolic BPs increased during the study pe-
riod as compared to the BP on the day of the diagnosis in the 
infants with a birth weight more than 1,500 g; however, there 
was no statistically significant difference between the two 
groups (Fig. 2).
Infants with a birth weight less than 1,500 g 
The mean systolic BP increased daily in the infants with a 
birth weight less than 1,500 g. However, the diastolic BP increas-
ed from the day before indomethacin treatment was started 
upto two days after indomethacin treatment in the infants 
with a birth weight less than 1,500 g. Systolic and diastolic BPs 
were significantly lower in the PDA group than in the control 
group during the same period. There were no significant differ-
ences in the pulse pressures between the two groups (Fig. 3). 
Infants with a gestational age of more than 30 weeks   
The systolic and diastolic BPs increased during the study 
period in the infants with a GA of more than 30 weeks as 
compared to the BP on the day of diagnosis. However, there 
were no statistically significant differences between the two 
study groups. The diastolic BP was lower in the PDA group 
Fig. 1. Mean systolic blood pressure (top), mean diastolic blood 
pressure (middle) and pulse pressure (bottom) in the PDA group 
and the control group. The closed squares indicate the PDA group 
and the open squares indicate the control group. Error bars indi-
cate the standard deviation. *p<0.05. PDA: patent ductus arteriosus.
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Fig. 2. Mean systolic blood pressure (top), mean diastolic blood 
pressure (middle) and pulse pressure (bottom) in the infants with 
a birth weight more than 1,500 g. PDA: patent ductus arteriosus.
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Fig. 3. Mean systolic blood pressure (top), mean diastolic blood pres-
sure (middle) and pulse pressure (bottom) in the infants with a bir-
th weight less than 1,500 g. PDA: patent ductus arteriosus. *p<0.05.
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Fig. 4. Mean systolic blood pressure (top), mean diastolic blood pres-
sure (middle) and pulse pressure (bottom) in the infants with a ges-
tational age more than 30 weeks. PDA: patent ductus arteriosus.
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Fig. 5. Mean systolic blood pressure (top), mean diastolic blood pres-
sure (middle) and pulse pressure (bottom) in the infants with a gesta-
tional age less than 30 weeks. PDA: patent ductus arteriosus. *p<0.05.
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to two days after indomethacin treatment and were signifi-
cantly lower as compared to the control group from the day be-
fore indomethacin treatment upto two days after indometh-
acin treatment. However, there were no significant differences 
in the pulse pressures between the two groups (Fig. 5). 
Discussion
The classical physical signs of a PDA are a heart murmur, ta-
chycardia, and wide pulse pressures presenting as bounding pul-
ses, a hyperactive precordium, and hepatomegaly. Chest ra-
diographs show pulmonary plethora, cardiomegaly and a wide 
angle between the left and right main bronchi due to left at-
rial dilatation. However, several studies on these clinical signs 
have shown a sensitivity that ranges from 37%
18) to 72%
19) with 
little added to the clinical findings on radiography.
20) Clearly, 
echocardiography is the most accurate method for establish-
ing the diagnosis and assessing the closure of a PDA; howev-
er, practically it is difficult for many neonatal units to have im-
mediate access to echocardiography. In the NICU, BP is ev-
aluated regularly in all the preterm infants. This study was 
performed to evaluate the change in BP before and after the 
treatment of a PDA and to determine whether the pulse pres-
sure BP is a useful clinical factor in the prediction and treat-
ment of a PDA. 
The results of this study show that in cases where medical 
treatment is successful, there is a gradual increase in the sys-
tolic and diastolic BPs after indomethacin treatment. A pro-
portionate increase in both the systolic and diastolic BPs was 
seen, which means that there was no change in the pulse pres-
sure. Therefore, if the systolic and diastolic BPs gradually in-
creased after indomethacin treatment, PDA closure can be 
expected. Infants with a PDA had a significantly lower mean 
systolic and diastolic BP as compared to the control infants. 
There were no significant differences in the pulse pressures 
between the two groups and both the systolic and diastolic 
BPs promptly returned to control values four days after treat-
ment with indomethacin. 
Prior studies have shown similar results. Ratner et al.
14) re-
ported that the systolic and diastolic BPs decreased at the time 
of diagnosis of the PDA; also there were no significant dif-
ferences in the pulse pressure. They suggested that the dia-
stolic BPs were a more sensitive indicator of significant duc-
tal shunting. However, the sample size in their study was small, 
including only 17 infants with a PDA and in these cases the 
PDA was surgically repaired.
Evans and Moor Craft
4) reported that a hemodynamically 
significant PDA in very preterm infants during the first week 
of life was associated with a reduction in both the systolic and 
diastolic BPs and the pulse pressure was not different from 
that in the infants without a PDA. The most dramatic reduc-
tions in BP were among the infants less than 1,000 g; in the 
infants between 1,000-1,500 g, the BP was not significantly 
different between the infants with and without a hemodyna-
mically significant PDA. However, in this study the change 
in the BP after treatment was not analyzed.
In other studies, Evans Iyer
11) found an increase in BP fol-
lowing PDA closure with inconsistent changes in the pulse 
pressure. Where medical treatment is successful, there is a gr-
adual and significant increase in all BP parameters over three 
days after the first dose of indomethacin, with inconsistent 
changes in the pulse pressure. They investigated the BP only 
in the PDA group and did not compare their findings to the 
infants without a PDA. It is well known that the BP gradual-
ly increases after birth in preterm infants.
21) It was difficult to 
determine in their study whether the increase in BP after me-
dical treatment was due to normal physiological changes or 
due to changes caused by the closure of the PDA. Therefore, 
to overcome this limitation, the BP in the PDA group was com-
pared to a control group matched for GA and BW. The results 
showed a significant difference in the systolic and diastolic BPs 
between the two study groups before and after treatment of 
the PDA.
Lubetzky et al.
9) found that PDA closure was associated with 
a non-significant change in the pulse pressure. However, they 
studied preterm infants that were diagnosed with a PDA wi-
thin the first 24 hours of life and reported the BP only two times, 
i.e., pre and post treatment.
This study included 72 neonates with a PDA, medically 
treated with indomethacin and 72 neonatal controls without 
a PDA. For the low birth weight infants less than 1,500 g or 
with a GA of less than 30 weeks, increase in the systolic and 
diastolic BPs were more significant when the PDA was he-
modynamically significant. 
In this study, infants with conditions that might have some 
influence on the BP such as intraventricular hemorrhage, ne-
crotizing enterocolitis, and sepsis as well as those that received 
surfactant infusion or ventilatory support were excluded. Fur-
ther studies including these factors, and evaluation of the use-
fulness of other clinical signs such as a heart murmur, pulse rate, 
and chest radiography, are needed. 
In conclusion, a widened pulse pressure is not a useful clin-
ical sign of a hemodynamically significant PDA in preterm 
infants. However, low systolic and diastolic BPs may be useful 
clinical signs of a hemodynamically significant PDA in pre-
term infants. If systolic and diastolic BPs are low, a PDA sh-
ould be considered and early assessment with echocardiog-
raphy should be performed for establishing the diagnosis and 
initiating the treatment of a PDA. The systolic and diastolic BPs 
gradually increased after treatment, and this was associated 
with PDA closure.
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